World's First Stem Cell Treatment to Restore Vision Offers New Hope for LSCD Patients

In a groundbreaking study, four patients suffering from limbal stem-cell deficiency (LSCD)—a disorder that causes severe corneal scarring and blindness—underwent an innovative treatment that could transform their lives. By receiving corneal cell transplants developed from induced pluripotent stem (iPS) cells, these patients became part of a revolutionary approach that holds new hope for restoring vision in those facing the challenges of this complex condition.Three of the four patients reported significant, long-lasting improvements in their eyesight for more than a year, while the fourth patient only saw short-term benefits. This novel method offers a viable alternative to LSCD, which frequently requires a high-risk corneal transplant from a healthy donor or the patient's other eye. A Prompt & Promising Procedure For the Future ~  The iPS-cell-based method, created by Dr. Kohji Nishida of Osaka University in Japan, entails transforming healthy blood cells to resemble embryos. After that, a transparent tissue sheet made from these cells is transplanted onto corneas that have been injured. This operation was performed on the four patients between 2019 and 2020.Remarkably, even in two individuals who did not take immunosuppressive medications, none of the transplanted  cells developed tumors or displayed symptoms of immunological rejection. Researchers hypothesize that the transplanted cells may have stimulated their own cells to promote corneal healing, as all four patients reported immediate improvements in vision after the treatment. This discovery may lead to more developments in stem cell-based eye treatments and provides a hopeful new option for people with LSCD to regain their sight.